Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suven Life Sciences (Suven), a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, has said that New Zealand Patent Office has issued a patent: 548743 and the Indian Patent Office has issued a patent: 238017 to its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
Subscribe to our email newsletter
Suven said that the patents are valid until 2024 and 2025 respectively. The granted claims of the patents include the class of selective 5-HT compounds discovered by the company and are expected to be developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, ADHD, Parkinson, Schizophrenia and Huntington’s diseases.
With these new patents, Suven claimed to have a total of 7 granted New Zealand product patents and 9 granted Indian product patents on NCEs. The granted patents are through the internal discovery research efforts. Products out of these inventions may be out-licensed at various stages of clinical development like at Phase-I or Phase-II.
Venkat Jasti, CEO of Suven, said: “We are very pleased by the grant of these 3 patents to Suven by Australian Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20bn market potential globally.”